Functional studies showed that BIDEN-AP could simultaneously activate EphB4-initiated Abl/Crk1 tumor-suppressive signaling in tumor cells and inhibit EFNB2-regulated angiogenic signaling in endothelial cells. This evidence concerns the gene EFNB2 and neoplasm.